Immunotherapy of brain metastases: breaking a “dogma”

被引：0
作者：
Anna Maria Di Giacomo
Monica Valente
Alfonso Cerase
Maria Fortunata Lofiego
Francesca Piazzini
Luana Calabrò
Elisabetta Gambale
Alessia Covre
Michele Maio
机构：
[1] Center for Immuno-Oncology,Department of Oncology
[2] Medical Oncology and Immunotherapy,Unit of Neuroradiology
[3] University Hospital of Siena,undefined
[4] University Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 38卷
关键词：
Brain metastases; Immune checkpoint(s); Cancer immunotherapy; Lung cancer; Magnetic resonance imaging; Melanoma; Neuroradiology; Tumor microenvironment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Until very few years ago, the oncology community dogmatically excluded any clinical potential for immunotherapy in controlling brain metastases. Therefore, despite the significant therapeutic efficacy of monoclonal antibodies to immune check-point(s) across a wide range of tumor types, patients with brain disease were invariably excluded from clinical trials with these agents. Recent insights on the immune landscape of the central nervous system, as well as of the brain tumor microenvironment, are shedding light on the immune-biology of brain metastases.
引用
收藏
相关论文
共 452 条
  • [31] Atkins MB(2019)3D models in the new era of immune oncology: focus on T cells, CAF and ECM J Exp Clin Cancer Res 38 117-886
  • [32] Subedi P(2019)Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment J Exp Clin Cancer Res 38 162-803
  • [33] Wu J(2019)Turning “cold” into “hot” tumors—opportunities and challenges for radio-immunotherapy against primary and metastatic brain Front Oncol 9 1-1492
  • [34] Chambers J(2019)Epigenetic classifiers for precision diagnosis of brain tumors Epigenet Insights 12 1-1563
  • [35] Mattingly TJ(2013)Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine containing demethylating dinucleotide Cancer Immunol Immunother 62 605-60
  • [36] Quail DF(2013)The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells Immunology. 138 105-730
  • [37] Joyce JA(2015)Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy Nature. 527 249-681
  • [38] Berghoff AS(2012)Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol. 13 459-40
  • [39] Venur VA(2012)Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Lancet Oncol. 13 879-265
  • [40] Preusser M(2015)Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study Ann Oncol 26 798-112
12345678910